Representative Tim Moore (R-North Carolina) recently bought shares of Centene Corporation (NYSE:CNC). In a filing disclosed on August 05th, the Representative disclosed that they had bought between $15,001 and $50,000 in Centene stock on July 21st.
Representative Tim Moore also recently made the following trade(s):
- Purchased $15,001 – $50,000 in shares of Krispy Kreme (NASDAQ:DNUT) on 7/30/2025.
- Purchased $15,001 – $50,000 in shares of Centene (NYSE:CNC) on 7/30/2025.
- Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 7/30/2025.
- Purchased $15,001 – $50,000 in shares of Verizon Communications (NYSE:VZ) on 7/29/2025.
- Purchased $15,001 – $50,000 in shares of Intel (NASDAQ:INTC) on 7/29/2025.
- Purchased $1,001 – $15,000 in shares of Krispy Kreme (NASDAQ:DNUT) on 7/29/2025.
- Purchased $15,001 – $50,000 in shares of Centene (NYSE:CNC) on 7/29/2025.
- Purchased $1,001 – $15,000 in shares of Centene (NYSE:CNC) on 7/22/2025.
- Purchased $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 7/21/2025.
- Purchased $15,001 – $50,000 in shares of Centene (NYSE:CNC) on 7/18/2025.
Centene Trading Down 2.7%
Shares of NYSE:CNC opened at $25.20 on Thursday. Centene Corporation has a 12-month low of $25.11 and a 12-month high of $80.59. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $12.37 billion, a P/E ratio of 6.24, a price-to-earnings-growth ratio of 1.06 and a beta of 0.40. The firm has a fifty day moving average of $42.15 and a two-hundred day moving average of $54.03.
Analyst Ratings Changes
Several brokerages have recently commented on CNC. Oppenheimer dropped their price target on shares of Centene from $51.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, July 28th. Truist Financial cut their target price on Centene from $42.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, July 28th. Wells Fargo & Company downgraded Centene from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $72.00 to $30.00 in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. lowered their price target on Centene from $48.00 to $30.00 and set a “neutral” rating on the stock in a report on Tuesday, July 29th. Finally, Robert W. Baird reduced their price objective on shares of Centene from $68.00 to $28.00 and set a “neutral” rating for the company in a research note on Friday, July 25th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $42.20.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in CNC. Invesco Ltd. boosted its stake in Centene by 5.1% during the first quarter. Invesco Ltd. now owns 11,091,964 shares of the company’s stock worth $673,393,000 after buying an additional 536,508 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Centene by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 11,049,494 shares of the company’s stock worth $669,820,000 after acquiring an additional 3,306,796 shares during the period. Ameriprise Financial Inc. increased its stake in Centene by 32.3% in the fourth quarter. Ameriprise Financial Inc. now owns 6,469,062 shares of the company’s stock valued at $391,854,000 after acquiring an additional 1,578,917 shares during the period. Northern Trust Corp raised its position in Centene by 9.1% in the fourth quarter. Northern Trust Corp now owns 5,294,816 shares of the company’s stock worth $320,760,000 after purchasing an additional 443,121 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Centene by 3.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,810,489 shares of the company’s stock worth $292,045,000 after purchasing an additional 143,573 shares during the period. Institutional investors own 93.63% of the company’s stock.
Insider Buying and Selling at Centene
In related news, Director Theodore R. Samuels II bought 9,000 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was acquired at an average price of $27.62 per share, for a total transaction of $248,580.00. Following the transaction, the director directly owned 32,000 shares of the company’s stock, valued at $883,840. This represents a 39.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.36% of the company’s stock.
About Representative Moore
Timothy K. Moore (Republican Party) is a member of the U.S. House, representing North Carolina’s 14th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Moore (Republican Party) ran for election to the U.S. House to represent North Carolina’s 14th Congressional District. He won in the general election on November 5, 2024.
Moore served as speaker of the House from 2015 to 2025.
Timothy Moore earned his B.A. from the University of North Carolina-Chapel Hill in 1992 and his J.D. from the Oklahoma City University School of Law in 1995. His professional experience includes working as an attorney.
Centene Company Profile
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Recommended Stories
- Five stocks we like better than Centene
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?
- How to Short Nasdaq: An Easy-to-Follow Guide
- How DigitalOcean’s Focus Is Fueling Explosive Growth
- High Flyers: 3 Natural Gas Stocks for March 2022
- Can Celsius Stock Keep Its Momentum Going Any Longer?
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.